Background-Catecholamines increase heart rate by augmenting the cAMP-responsive hyperpolarization-activated cyclic nucleotide-gated channel 4 pacemaker current (I f ) and by promoting inward Na ϩ /Ca 2ϩ exchanger current (I NCX ) by a "Ca 2ϩ clock" mechanism in sinoatrial nodal cells (SANCs). The importance, identity, and function of signals that connect I f and Ca 2ϩ clock mechanisms are uncertain and controversial, but the multifunctional Ca 2ϩ /calmodulindependent protein kinase II (CaMKII) is required for physiological heart rate responses to ␤-adrenergic receptor (␤-AR) stimulation. The aim of this study was to measure the contribution of the Ca 2ϩ clock and CaMKII to cardiac pacing independent of ␤-AR agonist stimulation. Methods and Results-We used the L-type Ca 2ϩ channel agonist Bay K8644 (BayK) to activate the SANC Ca 2ϩ clock.
T he fight-or-flight response to increase heart rate is a fundamental aspect of cardiovascular physiology, but recent findings have unsettled a core concept that increases in heart rate are exclusively due to a cAMP-activated pacemaker current (I f ). Accumulating data support a view that sinoatrial node (SAN) pacemaker automaticity is an outcome of cell membrane depolarization triggered by an inward 'pacemaker' current (I f ), conducted primarily by hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4), and an inward Na ϩ /Ca 2ϩ exchange current (I NCX ), activated by spontaneous Ca 2ϩ release from the sarcoplasmic reticulum (SR). [1] [2] [3] [4] Increases in I f and I NCX steepen the slope of phase 4 diastolic depolarization (DD), leading to faster SAN cell (SANC) action potential triggering. 4, 5 Catecholamines acti-vate the cAMP and protein kinase A (PKA) signaling pathway by agonist actions at ␤-adrenergic receptors (␤-ARs) and so have the capability of increasing I f , SR Ca 2ϩ release, and I NCX . 6 However, recent work suggests that SANCs also use a ␤-AR-independent mechanism for promoting cAMP activity by Ca 2ϩ -dependent activation of adenylyl cyclase. 7
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Despite the potential interconnections between ␤-ARinitiated and Ca 2ϩ -responsive signaling pathways for augmenting I f and I NCX to increase heart rate, we are unaware of any studies examining the signaling mechanisms engaged by increasing intracellular Ca 2ϩ , independent of ␤-AR agonist stimulation, in SANCs. Isoproterenol, a ␤-AR agonist, in-creases intracellular Ca 2ϩ in SANCs and activates the Ca 2ϩ / calmodulin-dependent protein kinase II (CaMKII). 8 We recently reported that CaMKII was required for the physiological heart rate response to isoproterenol, 9 but it is unknown whether CaMKII actions require ␤-AR activation or whether CaMKII activation in the absence of ␤-AR agonist stimulation is sufficient to increase heart rate. We designed our study to distinguish the contributions of Ca 2ϩ and ␤-AR signaling to SAN automaticity and to determine whether increases in intracellular Ca 2ϩ and CaMKII were capable of increasing SAN rates to a similar extent as ␤-AR stimulation.
Here, we increased SANC intracellular Ca 2ϩ directly, independently of ␤-AR stimulation, by increasing L-type Ca 2ϩ current (I Ca ) with BayK 8644 (BayK). BayK increased mouse and dog SANC automaticity over a dynamic range that was similar to increases evoked by isoproterenol, suggesting that a Ca 2ϩ -dependent mechanism is robust and capable of supporting the majority of heart rate increases required for the physiological fight-or-flight response in small and large animal models. 10, 11 BayK increased heart rate and SANC automaticity significantly less in Langendorff-perfused isolated mouse hearts and in isolated SANCs with CaMKII inhibition due to transgenic myocardial expression of a CaMKII inhibitory peptide (AC3-I) compared with wild-type (WT) littermates or transgenic control mice with myocardial expression of an inactive scrambled form of AC3-I (AC3-C). These findings suggested that heart rate responses to increased Ca 2ϩ relied on activation of CaMKII. BayK increased I Ca equally in AC3-I, AC3-C, and WT SANCs, showing that reduced BayK response in AC3-I SANCs was due to actions "downstream" to I Ca . The increases in rate by BayK were independent of I f because I f was not increased by BayK and was equivalent in AC3-I and control SANCs, suggesting that increasing SANC Ca 2ϩ with BayK did not activate a cAMP pathway with access to HCN4. Furthermore, BayK did not increase phosphorylation of a bona fide PKA phosphorylation target site on phospholamban (Ser16) in SANCs, suggesting that increasing SANC Ca 2ϩ does not lead to a generalized increase in PKA activity. BayK increases in SANC automaticity required SR Ca 2ϩ release because they were eliminated by ryanodine and because AC3-I SANCs failed to show increased frequency of late-diastolic SR Ca 2ϩ release events or enhanced I NCX in response to BayK compared with controls. These data show that CaMKII activation, independent of ␤-AR stimulation, can support heart rate increases over a dynamic range that is similar to the classical ␤-AR-agonist-stimulated fight-or-flight response. CaMKII is required for increasing heart rate by ␤-ARand Ca 2ϩ -based mechanisms in SANCs.
Methods
Methodological details are provided in the online-only Data Supplement Materials. Single SANCs from mouse and dog were isolated. 9, 12 We recorded action potentials, I f , and I NCX with perforated patch access; I Ca was recorded with conventional whole-cell mode. All voltage and current clamp studies were performed at 36°C. Intracellular Ca 2ϩ transients and sparks were measured with a confocal microscope (LSM510; Carl Zeiss MicroImaging) using the line scan mode, as described previously. 12, 13 Western blot analyses were performed to measure the phosphorylated (Ser16 or Thr17) and total phospholamban expression in SAN tissue. The data are presented as meanϮSEM. The statistical significance was evaluated with 1-way or 2-way ANOVA or Student t test as appropriate; Student-Newman-Keuls was used for post hoc analysis. PϽ0.05 was considered statistically significant.
Results

Equivalent SAN Rate Acceleration by BayK and ␤-AR Stimulation
We used a selective L-type Ca 2ϩ channel agonist, BayK, 14 to examine whether increasing I Ca affected the spontaneous activity of SANCs. The SANCs were perfused for at least 5 minutes with different concentrations of BayK. BayK significantly and dose dependently increased the pacemaking activity of SANCs isolated from WT mice ( Figure 1A and B) . Interestingly, the rate-dose response relationship to BayK was similar to the rate-dose response relationship observed with isoproterenol ( Figure 1B ). The maximum effects of BayK and isoproterenol were equivalent ( Figure 1C ). These findings showed that BayK and isoproterenol were similarly effective in increasing SANC automaticity. We next asked whether the rate response to BayK occurred in larger mammals and repeated our studies with canine SANCs. We found that BayK increased the spontaneous activity in single SANCs isolated from dogs, similar to our findings in mouse SANCs Figure 2 . SANC rate increases by BayK are reduced by CaMKII inhibition. A, Representative AP traces recorded before and after BayK in SANCs isolated from AC3-C and AC3-I mice. B, Spontaneous activity of SANCs in the absence and presence of 1 mol/L BayK. **PϽ0.01 versus control (nՆ16 cells from Ͼ4 animals for each group). C, SANC rate increases by BayK in WT, AC3-C, and AC3-I mice (data from B). **PϽ0.001 versus WT or AC3-C (nՆ16 cells from Ͼ4 animals for each group). D, BayK (1 mol/L) significantly increased the DDR in SANCs from WT and AC3-C but not AC3-I mice. **PϽ0.01 versus control; #PϽ0.05 versus WT and AC3-C mice (nՆ16 cells from Ͼ4 animals for each group). E, BayK did not significantly alter the MDP in any groups (data from D) (nՆ16 cells from Ͼ4 animals for each group). AC3-I indicates CaMKII inhibition by transgenic expression of an inhibitory peptide; AC3-C, inactive scrambled form of AC3-I; CaMKII, Ca 2ϩ / calmodulin-dependent protein kinase II; DDR, diastolic depolarization rate; WT, wild type. Other abbreviations as in Figure 1 . (online-only Data Supplement Figure 1 ). The rate increase by BayK in dog SANCs was close to what we found with isoproterenol. 12 These data indicate that BayK induces significant rate increases in SANCs isolated from mice and dogs, suggesting that studies of heart rate responses to BayK in mice also will provide information relevant to larger mammals.
CaMKII Is Required for BayK-Triggered Increases in SANC Rates
We recently reported that CaMKII is required for SAN fight-or-flight physiology during ␤-AR stimulation. 9 To test whether acceleration of SAN automaticity by L-type Ca 2ϩ channel activation, independent of ␤-AR stimulation, requires CaMKII, we measured the effects of BayK on isolated SANCs and Langendorff-perfused hearts from mice with cardiomyocyte-delimited expression of AC3-I. We used AC3-C-expressing mice and WT littermates as controls. 15 At baseline, the spontaneous activity was similar among AC3-I, AC3-C, and WT SANCs, consistent with our earlier report (Figure 2A and B) . 9 However, the rate increase in AC3-I SANCs after BayK was less than half of the BayK-triggered rate increase in controls ( Figure 2C ). These results showed that BayK-triggered increases in automaticity were significantly (Pϭ0.003) reduced in AC3-I compared with control SANCs. The rate increases by BayK were not eliminated by AC3-I expression likely because I Ca contributes directly to DD and because AC3-I inhibition of CaMKII activity is incomplete. 15 Similar to the isolated SANCs, there was no difference in the baseline beating rates in AC3-I, AC3-C, and WT Langendorff-perfused hearts. BayK increased the heart rates in all mice, but the increase in AC3-I hearts was significantly (Pϭ0.005) less than that in hearts from WT and AC3-C mice (online-only Data Supplement Figure 2 ). These results indicated that CaMKII is required for the full range of SANC rate response to BayK.
Reduced DD Rate Response but Preserved I f and I Ca in AC3-I SANCs
Modulating the spontaneous DD is the cell membrane potential mechanism for governing SANC rate. 16 At baseline, the DD rate (DDR) did not differ among the 3 genotypes. However, DDR increases by BayK in AC3-I mice were significantly (Pϭ0.01) less than in WT and AC3-C controls ( Figure 2D ). BayK did not significantly alter MDP ( Figure  2E ) or APD (data not shown) in any of the groups. Several Ca 2ϩ -sensitive adenylyl cyclases are expressed in SAN, suggesting the possibility that BayK may enhance the activity of the cAMP/PKA pathway. 17, 18 We next considered whether I f was involved in rate increases by BayK and measured I f from SANCs before and after BayK. BayK (1 mol/L) did not significantly affect I f in any of the groups (Figure 3 ). These results indicated that I f was unlikely to contribute to the reduced efficacy of BayK in AC3-I SANCs and suggested that increasing SANC Ca 2ϩ by BayK did not activate cAMP 19 or PKA 20 with access to HCN4. We next measured the PKA phosphorylation site (Ser16) on phospholamban 21, 22 to test for evidence of PKA activation by BayK, at a validated PKA target, in SANCs. We did not detect a significant increase in phospholamban Ser16 phosphorylation with BayK treatment (online-only Data Supplement Figure 3 ) compared with baseline. We interpret our findings to indicate that BayK increases heart rate by a mechanism that is not significantly determined by the cAMP/PKA signaling pathway in SANCs. We next measured I Ca to determine whether the reduced rate response to BayK in AC3-I SANCs was due to reduced I Ca responses in AC3-I compared with control SANCs. Consistent with our previous study, 9 there was no difference in the basal I Ca among the 3 genotypes ( Figure 4) . BayK equivalently increased peak and integrated I Ca in each of the genotypes, showing that reduced heart rate responses to BayK in AC3-I mice were independent of BayK actions on I Ca . Our data suggest that the reduced BayK response in AC3-I SANCs was determined by a cellular mechanism that was downstream to I Ca .
Ryanodine Prevented the SANC Response to BayK
Ca 2ϩ influx through I Ca is crucial for filling SR Ca 2ϩ stores and sustaining the capacity for the local Ca 2ϩ -release events from SR that are believed to contribute to SANC DDR and automaticity. 4, 9 Because CaMKII promotes SANC SR Ca 2ϩ release in response to isoproterenol, 9 we hypothesized that local SR Ca 2ϩ -release events underlie the rate increases by BayK. We used ryanodine, an SR Ca 2ϩ -release antagonist, to test whether BayK increases would persist in the absence of increases in local SR Ca 2ϩ -release events. Ryanodine (2 mol/L) reduced spontaneous automaticity equally in SANCs from AC3-I, AC3-C, and WT mice ( Figure 5 ). The SANC rate increases by BayK were significantly and equivalently blunted in all genotypes, suggesting that SR Ca 2ϩ release was essential for the differential effects of BayK on pacemaking activity in AC3-I compared with AC3-C and WT SANC.
CaMKII Inhibition Suppressed SR Ca 2؉ Release and BayK-Triggered Increases in I NCX
Because SR Ca 2ϩ release appeared to contribute to the effects of BayK on SANC pacemaking activity, we acquired confocal Ca 2ϩ images to directly measure SR Ca 2ϩ release events. BayK increased Ca 2ϩ -transient amplitudes to a similar level in SANCs from each of the 3 genotypes ( Figure 6A and B) . In contrast, BayK significantly increased the frequency of late-diastolic local Ca 2ϩ -release events in SANCs from WT and AC3-C but not AC3-I mice ( Figure 6C ). However, Ca 2ϩ spark amplitude, duration, and width remained unaltered by BayK in all the genotypes (data not shown). These results suggest that the reduced response of AC3-I SANCs stimulated with BayK was due to impaired diastolic SR Ca 2ϩ release, similar to the reduction in isoproterenol-stimulated SR Ca 2ϩ release in AC3-I SANCs. 9 Diastolic SR Ca 2ϩ release enhances I NCX in SANCs, and the increase in I NCX is critical for promoting DDR. 4, 23, 24 We next measured inward currents elicited with a voltage clamp ramp protocol from Ϫ60 to Ϫ45 mV, mimicking voltage range of spontaneous DD in SANCs, 25 at baseline and after BayK. The inward currents evoked by the voltage command protocol were predominantly I NCX because they were nearly eliminated by replacing Na ϩ with Li ϩ in the bath solution (online-only Data Supplement Figure 4 ). We found that BayK increased inward I NCX in WT and AC3-C mice significantly more than in AC3-I mice (Figure 7) . These results support the concept that CaMKII promoted increased diastolic Ca 2ϩ release to enhance I NCX and heart rate in response to BayK. 25, 26 
BayK Enhanced CaMKII Activity in SANCs
CaMKII becomes constitutively active in response to prolonged Ca 2ϩ exposure 27 by autophosphorylation of a threonine residue (Thr 286 or 287, depending on the isoform) in the CaMKII regulatory domain. 28 Our data up to this point strongly support a concept where CaMKII activation increases DDR and SANC rate by enhancing SR Ca 2ϩ release and I NCX . To assess the effects of BayK on SANC CaMKII activation, we measured threonine autophosphorylation (p-CaMKII) at baseline and during BayK (Figure 8 ). P-CaMKII was readily detected after BayK in WT and AC3-C but not in AC3-I SANCs. We found that p-CaMKII was enriched in a subsarcolemmal distribution after BayK in control SANCs. In contrast, p-CaMKII was not evident in SANCs from any of the mice without BayK under our experimental conditions. We found that BayK significantly increased phosphorylation of a bona fide CaMKII site on phospholamban (pThr17) in WT and AC3-C but not in AC3-I mice (online-only Data Supplement Figure 3 ). Taken together, these results show that BayK activates CaMKII under conditions permissive for increased SR Ca 2ϩ release and SANC rate increases and that AC3-I expression in SANCs is sufficient to inhibit BayKtriggered increases in CaMKII activity.
Discussion
The discovery of cAMP-gated ion channels 29 is a major milestone toward developing a molecular understanding of mechanisms for physiological cardiac pacing. The critical importance of I f to cardiac pacing in humans is highlighted by findings that patients with defects in I f due to mutations in the gene encoding HCN4 require surgical implantation of artificial pacemakers. 30 Recent data show that patients with heart failure benefit from new and highly selective I f antagonist drugs that reduce heart rate, 31 suggesting that hyperactivation of I f may contribute to heart disease in humans. We interpret the wealth of cellular and animal studies, in combination with the aforementioned clinical investigations, to provide incontrovertible evidence that I f is a fundamental mechanism for cardiac pacing. HCN4 is the predominant cAMP-gated ion channel for I f in SANC, 32 and new studies show that HCN4 also is activated by PKA phosphorylation. 20 Thus, ␤-AR agonist stimulation increases heart rate in part by enhancing SAN cAMP and PKA activity and increasing I f . However, mice with HCN4 knockout show a surprisingly mild phenotype and have normal or near-normal heart rate increases in response to isoproterenol. 33 These and other findings 9,12,34 support a view that HCN4-alternative mechanisms also support physiological cardiac pacing.
In the present study, we activated SANC automaticity by engaging the "Ca 2ϩ clock" mechanism, 4 independently of ␤-AR activation or I f , by using BayK. We found that BayK and isoproterenol increased SANC rates over a similar dynamic range, suggesting that the Ca 2ϩ -based mechanisms for cardiac pacing are capable of supporting a major component of fight-or-flight heart rate increases. Although the Ca 2ϩ clock is recruited in SANC by ␤-AR agonist stimulation under physiological conditions, the present study shows that the Ca 2ϩ clock can be activated even in the absence of ␤-AR receptor stimulation. Increased intracellular Ca 2ϩ may increase PKA activity in SANCs because of the relatively enhanced activity of Ca 2ϩ -activated adenylyl cyclase isoforms, principally types 1 and 8. 7, 18 The potential for Ca 2ϩactivated signaling molecules to affect I f has been posited as a mechanism for Ca 2ϩ -evoked increases in SAN automaticity. 3, 35 Thus, it is possible that BayK-induced increases in SANC automaticity could be a consequence of increased I f . However, we found no evidence that BayK-evoked increases in cellular Ca 2ϩ entry affected I f . We believe that our results provide strong evidence that the Ca 2ϩ clock is an independent cellular mechanism that can be clearly distinguished from I f .
SANCs show increased basal PKA activity compared with atrial and ventricular myocytes, 36 and increased PKA activity is hypothesized to play a critical role in promoting the SR Ca 2ϩ release and inward I NCX . 26, 37 Thus, it is possible that hyperactivation of the cAMP/PKA pathway in SANCs, probably because of a relative abundance of Ca 2ϩ -activated adenylyl cyclase isoforms, could enhance coupling of the I f and Ca 2ϩ clock cellular pacing mechanisms. Several studies have provided evidence showing that ␤-AR agonist stimulation increases heart rate by coordinate activation of I f and a Ca 2ϩ clock mechanism. 4, 5 The present study contributes new information by showing that the Ca 2ϩ clock can produce significant increases in heart rate and SANC automaticity by a mechanism requiring CaMKII in the absence of ␤-AR agonist stimulation. We did not identify evidence for Ca 2ϩactivated cAMP or PKA to increase I f or to phosphorylate phospholamban. Thus, we interpret our results to show that the Ca 2ϩ clock highly depends on CaMKII, whereas Ca 2ϩactivated increases in cAMP and PKA signaling to I f and phospholamban are dispensable, at least under these experimental conditions. The existence of a Ca 2ϩ -based mechanism for SANC pacing and the relative importance of I f and SR Ca 2ϩ release have become highly polemic issues, with some investigators denying the potential for a Ca 2ϩ -dependent, I f -independent mechanism to drive SANC automaticity. 3 We believe that our findings provide new clarity to this controversy by showing the Ca 2ϩ clock, in the absence of ␤-AR agonist stimulation, to be a highly effective cellular mechanism for SANC and cardiac pacing. In this study, we used BayK as an experimental tool to interrogate the Ca 2ϩ clock. Under physiological conditions, our results suggest that Ca 2ϩ clock activation by enhanced CaMKII may at least partially account for the heart rate increase in the fight-or-flight response.
CaMKII now appears to be an essential component of SANC automaticity because of ␤-AR agonists and BayK. As such, CaMKII represents a highly adaptable connection between I f and SR-based SANC pacing mechanisms. CaM- KII increases Ca V 1.2 current, and phosphorylation of Ca V 1.2 channel ␤ subunits, which are presumably shared by Ca V 1.3, leads to mode 2 gating, 38 a high activity state originally identified as a response to BayK. 39 By using BayK, we were able to circumvent the potentially confounding effects of CaMKII on SANC Ca 2ϩ entry by I Ca . Surprisingly, BayK activation of I Ca , in the presence of reduced CaMKII activity or impaired SR Ca 2ϩ release, was insufficient to significantly increase SANC automaticity. In contrast, CaMKII activity and SR Ca 2ϩ release coupled to BayK-enhanced I Ca effectively increased SANC rates by diastolic SR Ca 2ϩ release favoring DD because of inward I NCX . Although BayK failed to increase diastolic SR Ca 2ϩ release and consequent I NCX in AC3-I mice, BayK resulted in modest enhancement of SANC automaticity, suggesting that the increases of I Ca by BayK also directly contribute to phase 4 DD. SR Ca 2ϩ release is essential for myofilament activation during excitationcontraction coupling in myocardium, whereas increased diastolic SR Ca 2ϩ release is associated with arrhythmias and myopathy in ventricular and atrial myocardium. CaMKII hyperactivation, perhaps partly as a response to increased SR Ca 2ϩ , is now recognized to contribute to cardiomyopathy and arrhythmias. 40, 41 In contrast, diastolic SR Ca 2ϩ leak and CaMKII activation appear to be fundamental aspects of the physiological function of SANC. It will be interesting to learn whether hyperactivation of CaMKII in SANCs leads to defects in cardiac pacing and whether CaMKII inhibition could be used therapeutically to prevent excessive SANC firing rates in heart failure similar to the recent success of I f antagonists.
